Microbot Medical Inc. announces the exercise of certain outstanding preferred investment options to purchase shares of common stock, aiming for significant gross proceeds.
The offering is expected to occur in two tranches, with the first closing estimated to generate approximately $25.2 million and the second closing approximately $4 million.
The Company intends to use the proceeds for various purposes, including the development and commercialization of its LIBERTY Robotic System and acquisitions of complementary assets.
Gross Proceeds Potential
Up to $92.2 million in gross proceeds expected through the exercise of preferred investment options.
Exclusive Placement Agent
H.C. Wainwright & Co. acts as the exclusive placement agent for the offering.
Use of Proceeds
Funds to be utilized for development, commercialization, regulatory activities, acquisitions, and general corporate purposes.
- The offering signifies a strategic move by Microbot Medical to raise substantial funds for its business activities and expansion.
- The Company's decision to offer preferred investment options indicates confidence in its growth prospects and the strength of its products and technologies.
Microbot Medical's successful exercise of preferred investment options reflects investor confidence and provides a solid financial foundation for the Company's future endeavors.